MVP Act

The Medicaid VBPs for Patients Act (MVP Act) would establish a formal, nationwide framework for value-based purchasing arrangements (VBPs) in Medicaid and related price-reporting rules. It codifies the use of multiple best price points for drugs under VBPs (provided the arrangement is offered to all states), expands how VBPs affect price reporting and reimbursements (including special rules for installments and non-retail drug forms), and defines VBPs consistent with federal regulations. The bill also requires federal guidance on deploying VBPs for inpatient drugs under Medicaid, expands an anti-kickback safe harbor to cover VBP-related payments to states, and orders a Government Accountability Office (GAO) study to assess how VBPs affect access, outcomes, and costs, with a report due in 2029. Overall, the MVP Act aims to enable broader use of VBPs across Medicaid while providing guardrails, oversight, and transparency. The package would affect manufacturers, state Medicaid programs, patients, and federal program rules (Medicaid, Medicare price reporting, and anti-kickback enforcement). It seeks to align Medicaid with value-driven pricing approaches in the commercial market, while also introducing mechanisms to monitor and study its impact on access, disparities, and overall health system costs.